Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

Home/Insights/Future directions in microvascular mechanism

Future directions in microvascular mechanism

Treatment stratified by endotype, non-invasive diagnosis, and whether microvascular disease is one condition across organs.

Microcirculation and microvascular function

Stratified treatment

The clearest direction is matching treatment to endotype identified by coronary function testing, rather than empirical therapy for undifferentiated chest pain. Trials designed around stratification are the way the therapeutic question gets answered.

Making diagnosis accessible

Invasive coronary function testing is the reference standard and is available in few centres. Validated non-invasive diagnosis — with agreed thresholds across CMR, PET and echocardiography — is what would move this from specialist practice into routine cardiology.

Mechanism

Endothelial dysfunction, structural remodelling, capillary rarefaction, inflammation and perivascular fibrosis are all implicated, and their relative contribution is unresolved. Distinguishing them matters because they imply different targets.

The systemic question

Whether coronary microvascular dysfunction, cerebral small vessel disease, diabetic microangiopathy and renal microvascular disease share a common mechanism is a genuinely open and consequential question. If they do, a treatment developed in one may transfer; if they do not, cross-organ extrapolation is unsafe.

Sex differences as a research priority

The over-representation of women is not fully explained. Whether it reflects hormonal influence on vascular function, differences in disease mechanism, or differential referral and diagnosis is unresolved, and answering it requires studies designed and powered for sex-stratified analysis rather than adjusted for sex.

Methodological needs

Agreed diagnostic thresholds, core outcome sets including patient-reported angina burden, and trials long enough to assess events rather than only symptoms.

In short

What to take from this.

  • Stratify by endotype — undifferentiated treatment is why earlier trials failed.
  • Do not extrapolate between organ beds without evidence of shared mechanism.
  • Design for sex-stratified analysis, not sex adjustment.

Sources

  • Consensus documents on coronary vasomotor disorders
  • Literature on sex differences in ischaemic heart disease

This page reflects established understanding as at mid-2026 and is not a current-awareness service. Clinical and regulatory positions change; verify anything decision-relevant against a current source.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.